GRNA — Greenlight Biosciences Holdings PBC Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- $45.43m
- $37.72m
- $6.78m
Annual income statement for Greenlight Biosciences Holdings PBC, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 3 | 1.75 | 1.59 | 6.78 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 32.2 | 54 | 110 | 171 |
| Operating Profit | -29.2 | -52.3 | -109 | -164 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -28.6 | -53.3 | -112 | -166 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -28.6 | -53.3 | -112 | -167 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -28.6 | -53.3 | -112 | -167 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -28.6 | -53.3 | -112 | -167 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.233 | -0.433 | -0.913 | -1.26 |
| Dividends per Share |